Company: TELO
Filing Date: 2025-02-04
Form Type: 10-K
Source: 0001493152-25-004872
Chunk: 628

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-02-04
Form: 10-K
Item: Item 1C
Chunk 628
---
2024, we entered into a Confidential Separation and Mutual General Release Agreement (the “Separation Agreement”)
with Nathen Fuentes whereby we mutually agreed that Mr. Fuentes’ employment as our Chief Financial Officer ended as of June 18,
2024. Provided that Mr. Fuentes did not revoke the acceptance of the Separation Agreement and complied with the terms therein, we would
pay Mr. Fuentes from the date thereof an aggregate of $62,500 in equal installments over three months in accordance with our regular
payroll schedule. The amount was paid in accordance with the agreements and no amounts are still outstanding as of December 31, 2024.

62

Grants
of Plan-Based Awards in 2024

    Estimated
    Future Payouts Under Non-Equity Incentive Plan Awards  
    Estimated
    Future Payouts Under Equity Incentive 
    Plan Awards  
    All Other
    Stock Awards: Number of Shares of Stocks  
    All Other
    Option Awards: Number of Securities Underlying   
    Exercise or
    Base Price of Option  
    Closing stock
    price on Award  
    Grant Date
    Fair Value of Stock and Option  

    Grant  
    Threshold  
    Target  
    Maximum  
    Threshold  
    Target  
    Maximum  
    or
    Units  
    Options  
    Awards  
    date  
    Awards 
  
    Name 
    Date(1)  
    ($)  
    ($)  
    ($)  
    (#)  
    (#)  
    (#)  
    (#)  
    (#)  
    ($/Sh)  
    ($/Sh)  

    Erez Aminov, CEO 
     8/27/2024  
     -  
     -  
     -  
     -  
     -  
     -  
     -  
     1,960,170(2) 
    $5.02(4) 
    $5.26  
    $7,513,332 
  
    Michelle Yanez, CFO 
     8/27/2024  
     -  
        
     -  
     -  
     -  
     -  
     -  
     200,